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Haptens (i.e. biomolecules which molecular weight is lower than 10 kDa) determination by inductively
coupled plasma mass spectrometry (ICP-MS) is usually performed by means of competitive immuno-
assays. In these immunoassays, analyte quantiﬁcation is indirectly carried out using two different tracer
species (i.e. antibodies or antigen-protein conjugates). However, the beneﬁts (and drawbacks) derived
from using a given tracer species have not been systematically investigated so far. The goal of this work is
to evaluate the inﬂuence of the tracer species employed in competitive immunoassays on the analytical
ﬁgures of merit for aﬂatoxin M1 (AFM1) determination in milk samples. To this end, three different
strategies have been developed and evaluated, namely: (i) antibody binding inhibition assay (ABIA); (ii)
capture inhibition assay (CIA); and (iii) capture bridge inhibition assay (CBIA). Experimental results show
that the use of the antibody as tracer species (as in the ABIA approach) affords better analytical ﬁgures of
merit for AFM1 determination than using the antigen-protein conjugate as the tracer one (as in the CIA
and CBIA strategies). The limit of detection afforded by ABIA strategy (i.e. 0.1 ng kg1) for AFM1 deter-
mination was 1000-fold and 50-fold lower regarding the CIA and CBIA strategies, respectively. In the case
of the ABIA approach, the characteristics of the metal nanoparticle label employed to detect the tracer
species is critical on the analytical ﬁgures of merit. However, when the hapten-protein conjugates are
used as tracer species, immunocomplex formation is severely hampered by steric effects caused by the
protein moiety and, consequently, the characteristics of the metal nanoparticle label is not critical in the
immunoassay performance. The different immunoassay strategies were successfully validated for AFM1
determination in milk samples using a certiﬁed reference material of whole milk powder (ERM-BD283)
according to European Conformity guidelines for analytical methods of food contaminants anddlay).
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improve limits of detection up to 10-fold.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
The signiﬁcance of inductively coupled plasma mass spec-
trometry (ICP-MS) for biomolecule analysis has exponentially
increased over the last years [1]. The use of ICP-MS in this ﬁeld
offers several attractive features regarding other established ap-
proaches: (i) high sensitivity; (ii) speciﬁcity; (iii) compound-
independent detection sensitivity; (iv) multi-element capabilities;
(v) robustness; and (vi) easy coupling to separation techniques.
Initially, the analysis was limited to those species containing a
heteroatom detectable by ICP-MS. However, analytical ﬁgures of
merit were severely compromised since the heteroatoms, naturally
present in biomolecules (e.g. P, S, Se, As, etc.), suffer from low
sensitivity and (spectral and non-spectral) interferences due to
matrix components in biological samples (e.g. carbon, chloride,
etc.) [1,2]. To improve the analytical ﬁgures of merit, as well as to
address with the determination of non-containing heteroatom
biomolecules, different strategies have been proposed in the liter-
ature. First, the biomolecule can be derivatized through a chemical
reaction with a heteroatom or an organometallic compound [3,4].
The main drawback of this approach is the low selectivity of the
labelling procedure. Alternatively, the analyte of interest can be
labelled by means of an immunoreaction using a heteroatom-
labelled antibody [5,6]. Because of the great speciﬁcity of the
antigen-antibody reaction, biomolecules can be successfully
determined in complex mixtures. Heteroatoms labels used in
immunoassay includes: (i) transition metals [7,8]; (ii) lanthanides
[9e11]; (iii) metal nanoparticles [12e14]; and (iv) Quantum-Dots
[15]. A priori, the use of metal nanoparticles is the most advanta-
geous approach to improve analytical ﬁgures of merit (e.g. sensi-
tivity, LoD, etc.) due to the high number of atoms present in each
nanoparticle.
Non-competitive immunoassays have been traditionally
employed for the analysis of high molecular weight biomolecules
such as proteins, enzymes, etc. In this type of immunoassay, an
antibody is usually immobilized on a solid support to capture the
analyte present in the sample. Next, a different antibody, speciﬁc
for another part of the biomolecule, is used to detect the analyte
previously captured on the solid support (i.e. sandwich assay). The
latter antibody is previously labelled with a heteroatom detectable
by ICP-MS (e.g. lanthanides, Quantum-Dots, metal nanoparticles,
etc.) thus enabling analyte detection. The signal registered by the
ICP-MS is proportional to the analyte concentration in the sample.
Dealing with haptens (i.e. biomolecules which a molecular weight
is lower than 10 kDa), sandwich-based immunoassays cannot be
employed since the limited surface area of this type of molecules
does not allow to simultaneously accommodate two antibodies
[16]. Therefore, haptens are usually determined by means of
competitive-immunoassays. In this type of immunoassay, unlike
non-competitive immunoassays, the quantity used of the tracer
species is limited. Two different strategies have been mainly
described in the literature for competitive immunoassays with ICP-
MS detection so far. In the ﬁrst approach, the sample is spiked with
a limited amount of the antibody and the mixture is incubated on a
solid phase coated with an antigen-protein conjugate. Next, a
competitive reaction, for the limited number of the binding sites of
the antibody, is established between the antigen bound to the solidphase and that present in the solution. The amount of the antibody
retained on the solid support is inversely proportional to the an-
tigen present in solution. To determine the antibody retained on
the solid support, it should be previously labelled with a hetero-
atom [11]. Nevertheless, to preserve antibody activity and speci-
ﬁcity against the antigen, it could be also detected after an
immunoassay procedure using a metal-labelled secondary anti-
body with or without biotin-streptavidin signal ampliﬁcation
[11,12]. Alternatively, the competitive reaction can be also estab-
lished using the antigen-protein conjugate as tracer species [14,15].
In this case, the antigen-protein conjugate is initially labelled with a
heteroatom. Next, the sample is spiked with a limited amount of
the labelled antigen-protein conjugate and the mixture is incu-
bated on a solid phase coated with the antibody. Again, the amount
of tracer species (antigen-protein conjugate) retained on the solid
support is inversely proportional to the antigen present in the
liquid phase. Up to date, both strategies have been indistinctively
employed in the literature for the determination of herbicides (2,4-
dichlorophenoxyacetic acid [8]), hormones (thyroxine [10], pro-
gesterone [15]), toxins (ochratoxin A [12], aﬂatoxin M1 (AFM1) [13])
and antibiotics (chloramphenicol [14]). However, the beneﬁts (and
drawbacks) derived from using either the antibody or the antigen-
protein conjugate as the tracer species have not been investigated
thoroughly. On the other hand, up to date there are no studies
about the inﬂuence of the kind of heteroatom label employed on
the analytical ﬁgures of merit of this type of immunoassays, espe-
cially for metallic nanoparticles.
The goal of this work is to perform a systematic comparison of
different competitive immunoassays for hapten determination by
means of ICP-MS detection. To this end, different competitive im-
munoassays based on the use of either antibody or antigen-protein
conjugate as tracer species were investigated. Nanoparticles
covering different elements (Ag/Au) and sizes (40/80 nm) were
used throughout this work to evaluate their inﬂuence on the
analytical ﬁgures of merit. Finally, the methods developed have
been applied for the AFM1 analysis in milk samples. Aﬂatoxin M1
was selected as a model of hapten to evaluate the beneﬁts and
drawbacks of the different approaches, due to its high health risk
and restrictive legal requirements.2. Experimental
2.1. Reagents and materials
Primary rabbit polyclonal anti-aﬂatoxin M1 (AFM1) antibody
(pAb) (puriﬁed IgG fraction 1mgmL1) was obtained from Agrisera
(V€annas, Sweden) whereas secondary anti-rabbit IgG (whole
molecule) - Biotin antibody produced in goat (secondary Ab)
(1mgmL1) was from Sigma-Aldrich (Steinheim, Germany). Ac-
cording to the supplier, pAb is highly speciﬁc for AFM1 determi-
nation with low cross-reactivity against other aﬂatoxins (aﬂatoxin
B1 2%; aﬂatoxin B2, 0.4%; aﬂatoxin G1 0.4% and aﬂatoxin G2 0.1%).
Aﬂatoxin M1 from Aspergillus ﬂavus and AFM1-Bovine Serum
Albumin conjugate (AFM1-BSA) were purchased from Sigma-
Aldrich (Steinheim, Germany). Aﬂatoxins are carcinogenic com-
pounds. So, extracts and solutions should be handled with extreme
care. Gloves and other protective clothing were worn as safety
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dues can be destroyed using 5% sodium hypochlorite.
Streptavidin conjugated 40 and 80 nm Au nanoparticles and
Streptavidin conjugated 40 and 80 nm Ag nanoparticles were
obtained from Cytodiagnostics (Ontario, Canada).
Sodium carbonate, sodium hydrogen carbonate, monosodium
phosphate, disodium phosphate, sodium chloride, polyethylene
glycol sorbitan monolaurate (Tween 20) and HPLC-grade acetoni-
trile were purchased from Sigma-Aldrich (Steinheim, Germany).
Bovine serum albumin (BSA) was obtained from Biowest (Nuaille,
France) Iridium and rhodium 1000mg L1 stock solution was pro-
vided by Merck (Darmstadt, Germany). Thiourea, 69% w w1 nitric
acid and 35% w w1 hydrochloric acid were purchased from Pan-
reac (Barcelona, Spain).
Ultrapure water 18MU cm from a Milli-Q system (Milli-Q water
puriﬁcation system, Millipore Inc., Paris, France) was used
throughout the work.
Immunoafﬁnity columns (IACs) Aﬂa M1 (Vicam, Watertown,
MA) with a capacity of approximately 150 ng and based on
monoclonal antibodies were employed for AFM1 determination in
milk samples. Amicon Ultra-4 Centrifugal Filter Units with Ultracel-
10 membrane (Merck Millipore, Cork, Ireland) were used
throughout the work for washing steps during the biotin labelling
of the AFM1-BSA conjugate.
For the immunoassays, F16 maxisorp polystyrene microtiter
plates were purchased from Thermo- Scientiﬁc (Roskilde,
Denmark) and used in all immunoassays.
2.2. Buffers and solutions
The standard stock solution of AFM1 (5 mgmL1) was prepared
by dissolving the standard AFM1 in pure acetonitrile. Working so-
lutions for standards or spiked milk samples were prepared by
further dissolution of stock solution in incubation media or in milk,
respectively. Aﬂatoxin M1-BSA conjugate was dissolved in phos-
phate buffer saline solution for a ﬁnal concentration of 500 mgmL1.
Both solutions were kept at20 C in aliquots out of direct light and
working solutions were prepared prior to each analysis. Primary
rabbit polyclonal antibody was stored at 4 C after reconstitution in
500 mL ultrapure water.
The following solutions were employed in the different immu-
noassays tested: (i) phosphate-buffered saline (PBS; 10mM
NaH2PO4, 2mM Na2HPO4, 154mM NaCl, pH 7.6); (ii) carbonate
buffer solution (15mMNa2CO3 and 35mMNaHCO3, pH 9.6); (iii) as
plate blocking medium: 1% w V1 BSA in PBS; (iv) as incubation
medium: 1% w V1 BSA and 0.05% V V1 Tween 20 in PBS; (v) as
washing medium: 0.05% V V1 Tween 20 in PBS; (vi) as Au-
nanoparticles digestion medium: 4% V V1 nitric acid and 12% V
V1 hydrochloric acid; and (vii) as Ag-nanoparticles digestion
medium: 2% V V1 nitric acid. It is important to remark that the use
of BSA in the incubation media is critical to ensure immunoassay
reproducibility. Considering that the pAb was produced in rabbits
by immunization with BSA haptenized with AFM1, the pAb could
react either with the AFM1 or BSA present in the AFM1-BSA con-
jugate. Moreover, bovine milk contains a signiﬁcant amount of this
protein (z1.2% w V1). Therefore, we employed BSA as an additive
in all incubation media and could consequently minimize
nonspeciﬁc binding.
2.3. Immunoassay procedures
In the present work, three different competitive immunoassay
strategies based on the use of either antibody or antigen-protein
conjugate as tracer species were evaluated for AFM1 determina-
tion by means of inductively coupled plasma mass spectrometry(ICP-MS) detection (Fig. 1).
2.3.1. Antibody binding inhibition assay (ABIA)
This immunoassay is based on that described in our previous
work [13] in which an antibody was employed as tracer species
(Fig. 1). Brieﬂy, the competitive reaction was established between
the AFM1 present in the sample and the AFM1-BSA conjugate,
coating the solid phase, for the limited number of the binding sites
of the antibody (pAb) spiked in the sample solution (Fig. 1, step
1.1e1.3). A biotinylated secondary Ab (Fig. 1, step 1.4) and
streptavidin-metal nanoparticle conjugate (Fig. 1, step 1.5) were
employed to detect the pAb retained on the solid phase. The in-
cubation conditions employed are described in our previous work
[13].
2.3.2. Capture inhibition assay (CIA)
This procedure is based on that previously reported by Trapiella-
Alfonso et al. [17] inwhich a labelled antigen-protein conjugate (i.e.
biotinylated AFM1-BSA) was used as the tracer species. In this case,
the competitive reaction was established between the AFM1 pre-
sent in the sample and the biotinylated AFM1-BSA conjugate
(spiked to the sample) for the limited number of the binding sites of
the pAb immobilized on the solid phase. Streptavidin-metal
nanoparticle conjugate was employed to detect the biotinylated
AFM1-BSA conjugate retained on the solid phase. Next CIA pro-
cedure is brieﬂy described. First, plates were coated at room tem-
perature with 100 mL/well of the appropriate pAb concentration in
0.05M carbonateebicarbonate buffer (pH 9.6). After incubation for
1 h, plates werewashed three times and then blocked (200 mL/well)
for 1 h at room temperature. Next, after a washing step, samples or
AFM1 standards and the appropriate biotinylated AFM1-BSA con-
jugate nominal concentration were mixed (Fig. 1, step 2.1) and
transferred to the solid phase (Fig. 1, step 2.2). The mixture was
incubated for 1 h at room temperature and, after a washing step
(Fig. 1, step 2.3), 100 mL/well of streptavidin-metal nanoparticle
conjugates solution was added and incubated for 1 h at room
temperature (Fig. 1, step 2.4).
2.3.3. Capture bridge inhibition assay (CBIA)
This immunoassay is based on the CIA procedure but the
competitive reaction is carried out in solution. A mixture of the pAb
and the biotinylated AFM1-BSA conjugatewas spiked to the sample.
The competitive reaction was established between the biotinylated
AFM1-BSA conjugate and the AFM1 present in the sample for the
limited number of the binding sites of the pAb. Next, and given the
bivalent nature of the antibodies, the AFM1-pAb and the bio-
tinylated AFM1-BSA-pAb complexes generated were retained by
the AFM1-BSA conjugates coating the solid phase. Streptavidin-
metal nanoparticle conjugates were used again to detect the bio-
tinylated AFM1-BSA-pAb complexes retained on the solid phase.
This immunoassay strategy has never been employed for hapten
analysis with to the best of author's knowledge.
The CBIA immunoassay procedure is carried out as follows.
Plates were coated at room temperature with 100 mL/well of the
appropriate AFM1-BSA conjugate concentration in 0.05M
carbonateebicarbonate buffer (pH 9.6). After incubation for 1 h,
plates were washed three times and then blocked (200 mL/well) for
1 h at room temperature. Then, after a washing step, samples or
AFM1 standards, pAb and biotinylated AFM1-BSA conjugate solu-
tions were mixed (Fig. 1, step 3.1) and transferred to the solid phase
(100mL/well) (Fig. 1, step 3.2). Next, the mixture was incubated for
1 h at room temperature. After a washing step (Fig. 1, step 3.3), 100
mL/well of streptavidin-metal nanoparticle conjugates solution was
added and incubated for 1 h at room temperature (Fig. 1, step 3.4).
The biotinylated AFM1-BSA conjugate required for the CIA and
Fig. 1. Scheme of the different competitive immunoassays tested in this work.
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kit. Brieﬂy, 2.3mg of succinimidyl-6-(biotinamido)hexanoate was
dissolved in 500 mL of dimetylformamide and then added to a
200 mL AFM1-BSA conjugate solution. The reaction was carried out
on ice for 2 h in the dark and the excess of non-reactive biotin re-
agent was removed on a cutoff ﬁlter by centrifugationwith PBS and
recovered at a nominal concentration of 150 mgmL1. The bio-
tinylated AFM1-BSA conjugate solution was divided into single
working aliquots and stored at 20 C.
For all strategies, the inﬂuence of the nanoparticle chemical
nature (i.e. Ag and Au) and size (i.e. 40 and 80 nm) on the analytical
ﬁgures of merit was investigated. In all cases, after dissolution of
the Au or Ag labelled streptavidin with 150 mL/well of the corre-
sponding digestion acid (300min at room temperature [12]), 50 mL/
well of a 1% w V1 thiourea solution containing 2.5 mg L1 of the
corresponding internal standard (IS) (see section 2.5) were added
for a ﬁnal volume of 200 mL/well and measured by ICP-MS. For the
different immunoassays, Ag and Au concentration per well after the
digestion procedure ranged approximately from 100 mg L1 to
8000 mg L1. Standards and samples containing unknown AFM1
amounts were run in triplicate wells and in quintuplicate wells,
respectively, and the mean values were processed.
2.4. Instrumentation
AﬂatoxinM1was indirectly quantiﬁed bymeans of ICP-MS using
the signal of the element present in the nanoparticle (107Agþ or
197Auþ). Experimental measurements were carried out on a quad-
rupole ICPMS model 7700x (Agilent, Santa Clara, USA). Table 1
gathers the operating conditions employed in this work.
Amicronebulizer (OneNeb®, Ingeniatrics, Sevilla, Spain) coupled
to a double pass quartz spray chamber (Agilent, Santa Clara, USA)
was employed to introduce the sample in the plasma. Because ofthe limited volume of sample available in the immunoassay
(200 mL), samples were introduced into a carrier stream by means
of a V-451 ﬂow injection manifold (Upchurch Scientiﬁc, Silsden,
United Kingdom) equipped with a 75 mL loop valve and driven to
the nebulizer by a peristaltic pump (Model Minipulse 3, Gilson,
France). Carrier ﬂow rate was set at 0.6mLmin1 for high
throughput analysis.
Two different carrier solutions were selected depending on the
chemical nature of the nanoparticle. A mixture of 1% V V1 nitric
acid and 1% w V1 thiourea solution was employed for 107Agþ
measurements whereas a 1% V V1 hydrochloric acid and 1% w V1
thiourea mixture was employed as carrier for 197Auþ determina-
tion. Operating in this way, no signiﬁcant memory effects were
registered in ICP-MS [18]. Microsoft Excel software was employed
to integrate peak signals manually, given the peak-shape signal
obtained with the ﬂow injection analysis device employed.
2.5. Calibration
Internal standardization is one of the useful techniques for
correction of instrument parameter ﬂuctuation in ICP-MS. In this
work, 103Rhþ and 193Irþ (at ﬁnal concentrations of 2.5 mg L1 each
one (section 2.3)) were used as an IS for 107Agþ and 197Auþ mea-
surements, respectively, due to their close atomic numbers and
ionization potentials [19].
Irrespective of the immunoassay strategy employed, standard
curves were obtained by plotting the metal/IS signal ratio against
the logarithm of the analyte concentration because of the sigmoidal
curve response of the competitive immunoassay procedure.
2.6. Samples
A certiﬁed reference material of whole milk powder (ERM-
Table 1
Operating conditions employed in ICP-MS.
Agilent 7700x ICP-MS
Plasma forward power (W) 1550
Argon ﬂow rate (L min1):
Plasma 15
Auxiliary 0.9
Nebulizer 1.01
Sample introduction system
Nebulizer OneNeb micronebulizer®
Spray chamber Double pass
Carrier ﬂow rate (mL min1) 0.6
Integration time (s) 0.5
Number of sweeps 100
Replicates 90
Signal nature Area
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Belgium) containing 111± 18 ng kg1 of AFM1 was employed for
the accuracy studies. In addition, four commercial cow milk sam-
ples obtained from retail markets were analyzed through this work.
All the samples were stored at 4 C and analyzed before their
respective expiration dates.
2.7. Sample preparation
The ERM-BD283 milk powder (10.0 g) was suspended in 100mL
of warm ultrapure water (being AFM1 ﬁnal concentration of
11.1± 1.8 ng L1), and then processed as for milk samples.
All milk samples were pre-treated before the analysis to miti-
gate interferences caused by matrix components (e.g. proteins,
lipids, etc.) since, otherwise, accuracy and precision would be
severely compromised. To this end, two different approaches were
employed through this work depending on the immunoassay
employed. In the case of ABIA strategy, samples were pretreated, as
described in our previous work [13], using the procedure described
by Huang et al. [20] based on an extraction pretreatment into a
polar solvent. On the other hand, in the case of using the antigen-
protein conjugate as tracer species, milk samples were pretreated
using immunocolumns following the procedure suggested by the
manufacturer with some minor modiﬁcations. Brieﬂy, a 100mL
volume of undiluted milk was centrifuged at 1614g for 15min to
separate the fat and thin upper fat layer was discarded. Fifty mL of
the centrifuged milk were passed through the immunoafﬁnity
column at 1e2 drops/second by gravity. Then, the column was
washed with 10mL of water at a rate of 1e2 drops/second until air
came through the column. Aﬂatoxin M1 was eluted slowly from the
column with 4mL of pure acetonitrile at 1 drop/2e3 s by gravity.
Two hundred mL of the sample eluate were evaporated up to dry-
ness. The residue was reconstituted with 100 mL of PBS and then
analyzed.
3. Results and discussion
Competitive immunoassays described in the literature show
several differences on the experimental setup according to the
tracer species monitored: i.e., the antibody [12,13] or the antigen-
protein conjugate [14,15]. For the ﬁrst time, immunoassays based
on both approaches are compared under a similar set of experi-
mental conditions for AFM1 analysis.
3.1. Optimization of the immunoassay procedures
The optimization of the immunoassays tested was performed by
means of checkerboard titration experiments as previouslydescribed for Enzyme Linked Immunosorbent Assay (ELISA) [21,22].
The optimum conditions were deﬁned as the amount of reagents
producing a metal-to-IS signal ratio (197Auþ/193Irþ; 107Agþ/103Rhþ)
in ICP-MS close to 80% of the maximal signal at plateau, charac-
teristic of tracer excess conditions [21].
3.1.1. Antibody binding inhibition assay
In our previous work [13], ABIA experimental conditions were
optimized using streptavidin-40 nm Au nanoparticle conjugates for
AFM1 determination in milk samples. The limit of detection (LoD)
was observed to be strongly dependent on the pAb concentration.
As long as the heteroatom-label allowed the accurate detection of
the pAb retained on the solid phase, detection capabilities of AFM1
could be improved decreasing the pAb concentration. In this
context, high sensitive heteroatom labels are required in ICP-MS to
decrease pAb concentration such as metal nanoparticles. For the
ﬁrst time, this works explores the inﬂuence of nanoparticle char-
acteristics on the analytical ﬁgures of merit for a competitive
immunoassay based on the use of antibodies as tracer species. To
this end, nanoparticles of different chemical nature (Au and Ag) and
size (80 nm and 40/80 nm, for Au and Ag, respectively) conjugated
to streptavidin were investigated. For each of them, the following
concentrations were optimized: (i) AFM1-BSA conjugate; (ii) pAb;
and (iii) streptavidin-metal nanoparticle conjugates. As in our
previous work [13], the concentration of the secondary Ab was not
optimized and the value recommended by the manufacturer was
employed (0.5 mgmL1). For the sake of comparison, previous data
using streptavidin-40 nm Au nanoparticle conjugates were
employed [13].
First, the optimum AFM1-BSA conjugate concentration and the
optimum pAb concentration were investigated. The AFM1-BSA
conjugate concentration was modiﬁed between 0.07 and
10 mgmL1 whereas the pAb concentration ranged from 0.015 to
2 mgmL1. The streptavidin-metal nanoparticle conjugates con-
centration was kept at 0.08 mgmL1 for these experiments. The
optimum AFM1-BSA conjugate concentration was similar for all
streptavidin-metal nanoparticle conjugates (i.e. 0.35 mgmL1), but
signiﬁcant differences were noted on the optimum pAb concen-
tration. The optimum pAb concentration using both 80 nm Ag and
Au nanoparticles was 0.015 mgmL1 whereas it was 0.25 mgmL1
for 40 nm Ag nanoparticles (Table S1). Interestingly, the optimum
pAb concentration using 40 nmAg nanoparticles was similar to that
previously found for 40 nm Au counterparts [13]. From these
ﬁndings, it could be derived that for this assay, the analytical ﬁgures
of merit afforded are expected to be strongly dependent on the size
of the nanoparticle employed. Fig. 2 shows the inﬂuence of the pAb
concentration on the LoD (calculated as three times the standard
deviation of the signal of 15 blank replicates [21,23]) using the
different streptavidin-Au and Ag nanoparticle conjugates. Experi-
mental data for 40 nm Au nanoparticles were measured following
previously reported experimental conditions [13]. The only differ-
ence between the experimental set up of the metal nanoparticles
investigated was the pAb concentration employed. So, it was
feasible to directly evaluate the inﬂuence of the pAb concentration
on the LoD. As expected, irrespective of the metal nanoparticle
considered, LoD decreased when the pAb concentration was
decreased. Under optimum pAb concentration, streptavidin-80 nm
Au nanoparticle conjugates afforded a LoD of 0.1 ng kg1, i.e. 50-fold
lower than that obtained with the 40 nm Au counterparts. Similar
ﬁndings were observed for Ag nanoparticles but the LoD obtained
were signiﬁcantly higher than those obtained using Au nano-
particles. Thus, the LoD for 80 nm and 40 nm Ag nanoparticles were
2 and 12 ng kg1, respectively. The origin of these differences is not
totally clear; since for a given nanoparticle size, optimum immu-
noassay conditions does not depend on the chemical nature of the
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197Auþ sensitivity in ICP-MS is higher than that of 107Agþ, mainly
due to the isotopic abundance of each nuclide (107Agþ 51.8%; 197Auþ
100%). Therefore, and considering that a competitive-based
immunoassay is operated, Au nanoparticles of the same size
allow a better discrimination of low AFM1 levels with regard to Ag
counterparts (See Fig. S1). On the other hand, it is also worth to
stress that the use of Ag nanoparticles was tricky due to a build-up
of Agmetallic deposits into the injector tube that could even lead to
full blockage. This phenomenon was also noticed for Au nano-
particles but the metallic deposit formationwas signiﬁcantly lower.
The inﬂuence of the streptavidin-metal nanoparticle conjugates
concentration on the analytical ﬁgures of merit was also investi-
gated. This parameter was modiﬁed between 0.02 and
0.32 mgmL1. It was observed that signals registered by the mass
spectrometer increased with the streptavidin-metal nanoparticle
conjugates concentration, but no changes were found in the opti-
mumpAb and AFM1-BSA conjugate concentration and, therefore, in
the LoD obtained for the nanoparticles tested (Table S2). For this
reason, regardless of the streptavidin-metal nanoparticle conjugate
used, a concentration of 0.08 mgmL1 was selected for further
studies as a compromise between analytical performance and cost.
These results were similar to those previously reported for 40 nm
Au nanoparticles [13]; thus, pointing out that this parameter was
not critical for the immunoassay performance.
Table 2 summarizes the optimum immunoassay conditions for
each streptavidin-metal nanoparticle conjugate investigated. This
table also includes the concentration of AFM1 giving rise to a 50%
inhibition (IC50), LoD and the lower and the upper quantiﬁcation
limits (lLoQ and uLoQ, respectively). The lLoQ was deﬁned as the
lowest concentration that signal response has repeatability lower
than 20% [24]. Similarly, the uLoQ was deﬁned as the highest
concentration that signal response has repeatability lower than 20%
[24]. These analytical ﬁgures of merit were calculated from the
corresponding calibration curves (Fig. 3) [21]. As expected by the
changes observed on detection capabilities, IC50, lLoQ and uLoQ
depended on the streptativin-metal nanoparticle conjugate
employed. For instance, IC50, lLoQ and uLoQ experimental values
for streptavidin-80 nm Au nanoparticle conjugates were 3 ng kg1,
0.3 ng kg1 and 100 ng kg1, respectively. Nevertheless, theFig. 2. Inﬂuence of the pAb concentration on the limits of detection for AFM1 deter-
mination by means of ABIA procedure using different streptavidin-metal nanoparticles
conjugates. (x) Ag-40 nm; ( ) Ag-80 nm; ( ) Au-40 nm; ( ) Au-80 nm. Aﬂatoxin M1-
BSA conjugate concentration: 0.35 mgmL1; secondary Ab concentration: 0.5 mgmL1;
streptavidin-metal nanoparticle conjugates concentration: 0.08 mgmL1. Each bar
represents the mean± t$s$n1/2 for three determinations (P¼ 95%).dynamic range for the different nanoparticles tested was similar.
3.1.2. Capture inhibition assay
Variables selected for the optimization of this immunoassay
were the concentration of: (i) pAb; (ii) biotinylated AFM1-BSA
conjugate; and (iii) streptavidin-metal nanoparticle conjugates.
Table 2 summarizes the optimum immunoassay conditions as well
as some relevant analytical ﬁgures of merit (i.e. IC50, LoD, lLoQ and
uLoQ) for this immunoassay.
First, the pAb concentration and the biotinylated AFM1-BSA
conjugate nominal concentration were optimized. The pAb con-
centration ranged from 0.6 to 10 mgmL1 whereas the biotinylated
AFM1-BSA conjugate nominal concentration was tested between
0.02 and 1.5 mgmL1. For these experiments, the streptavidin-metal
nanoparticle conjugates concentration was kept constant at
0.08 mgmL1. Experimental results showed that the optimum
conditions were 2.5 mgmL1 for pAb and 0.05 mgmL1 for bio-
tinylated AFM1-BSA conjugate (Table S3). Next, the inﬂuence of the
streptavidin-metal nanoparticle conjugates concentration on the
analytical ﬁgures of merit was investigated. This parameter was
modiﬁed between 0.02 and 0.32 mgmL1. As it was shown for ABIA
strategy, 107Agþ or 197Auþ signals increased with the streptavidin-
metal nanoparticles conjugate concentration but no signiﬁcant
changes were found in the optimum pAb and biotinylated AFM1-
BSA conjugate nominal concentration previously obtained as well
as on the LoD (Table S4). Therefore, the streptavidin-metal nano-
particles conjugate concentration was kept at 0.08 mgmL1 to
minimize operative cost. Under these experimental conditions, for
each of the streptavidin-metal nanoparticle conjugates (Fig. 4), a
calibration curve was prepared. A LoD of 100 ng kg1 was always
obtained, regardless of the size and the chemical nature of the
nanoparticle employed (Table 2). Though this value was similar to
that previously reported for progesterone analysis [15] using an
antigen-protein conjugate as tracer species, it was signiﬁcantly
higher than the value obtained by means of ABIA strategy. To
improve the LoD, the inﬂuence of incubation time of AFM1 and
biotinylated AFM1-BSA conjugate mixture on the microtiter plate
was studied, since it could favor tracer species retention on the
solid phase; thus, making feasible to use lower tracer species
concentrations [13]. The incubation time was increased from 1 to
10 h, but no signiﬁcant improvement on the analytical ﬁgures of
merit was obtained (Table S5). From these ﬁndings, the detection
capability is thought to be derived from the immunoassay pro-
cedure itself. It should be considered that, given the size of the BSA
moieties (66 kDa), high steric effects are expected when bio-
tinylated AFM1-BSA conjugates are captured by the pAbs coating
the microtiter plate. Obviously, steric effects are more signiﬁcant as
the AFM1 content in the sample decreases since more biotinylated
AFM1-BSA conjugates are captured on the solid phase. To address
this issue, some modiﬁcations were implemented in this type of
immunoassay to favor the immunocomplex formation. Thus, the
immunocomplexes were generated in a homogeneous phase rather
than in a heterogeneous phase; minimizing steric effects and, given
that the antibodies are bivalent molecules, the immunocomplexes
formed were retained in a microtiter plate coated with the antigen-
protein conjugate. To our best knowledge, this is the ﬁrst time that
this strategy is employed for hapten analysis. From now on, as
mentioned above, this immunoassay will be called capture bridge
inhibition assay (CBIA).
The optimization of CBIA was carried out likewise the CIA pro-
cedure but including the concentration of the AFM1-BSA conjugates
coating the microtiter plate. After some preliminary test, this con-
centration was observed to be not critical for the immunoassay.
This reagent had just to be in excess to maximize the immuno-
complex capture and, hence, this parameter was kept at 1 mgmL1.
Table 2
Optimum experimental conditions, limit of detection and dynamic range for the different immunoassay strategies.
Parameter ABIA CIA CBIA
Nanoparticle Ag Au Ag/Au (40/80 nm) Ag/Au (40/80 nm)
40 nm 80 nm 40 nma 80 nm
AFM1-BSA conjugate (mg mL1) 0.35 0.35 0.35 0.35 e 1
pAb (mg mL1) 0.25 0.015 0.24 0.015 2.5 2.0
Biotinylated secondary-Ab (mg mL1) 0.5 e e
Biotinylated AFM1-BSA conjugate (mg mL1) e 0.05 0.04
Streptavidin-metal nanoparticle conjugate (mg mL1) 0.08
IC50 (ng kg1) 310 30 42 3 1250 78
LoD (ng kg1) 12 2 5 0.1 100 5
lLoQ -uLoQ (ng kg1) 30e5000 6e1250 10e2500 0.3e100 300e5000 15e1250
a Data taken from Ref. [13].
Fig. 3. Aﬂatoxin M1 calibration curve using different streptavidin-metal nanoparticle
conjugates for the ABIA procedure. (x) Ag-40 nm; ( ) Ag-80 nm; ( ) Au-40 nm; ( ) Au-
80 nm. Aﬂatoxin M1-BSA conjugate concentration: 0.35 mgmL1; pAb concentration:
0.25 mgmL1 (Ag-40 nm), 0.24 mgmL1 (Au-40 nm), and 0.015 mgmL1 (Au-80 nm and
Ag-80 nm); secondary Ab concentration: 0.5 mgmL1; streptavidin-metal nanoparticle
conjugates concentration: 0.08 mgmL1. Each bar represents the mean± t$s$n1/2 for
three determinations (P¼ 95%).
Fig. 4. Aﬂatoxin M1 calibration curve using different streptavidin-metal nanoparticle
conjugates for the CIA procedure. (x) Ag-40 nm; ( ) Ag-80 nm; ( ) Au-40 nm; ( ) Au-
80 nm. Primary antibody concentration: 2.5 mgmL1; biotinylated AFM1-BSA conju-
gate: 0.05 mgmL1 and streptavidin-metal nanoparticle conjugates concentration:
0.08 mgmL1. Each bar represents the mean± t$s$n1/2 from three determinations
(P¼ 95%).
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the biotinylated AFM1eBSA conjugate nominal concentration and
the pAb concentration. To this end, the pAb concentration was
modiﬁed from 0.125 to 2 mgmL1 whereas the biotinylated AFM1
eBSA conjugate nominal concentration was tested from 0.01 to
0.64 mgmL1. During this optimization, a streptavidin-metal
nanoparticle conjugates concentration of 0.08 mgmL1 was
employed. A satisfying compromise between an optimum analyt-
ical sensitivity with a consistent readout was obtained using
2 mgmL1 pAb and 0.04 mgmL1 biotinylated AFM1-BSA conjugate
for all streptavidin-metal nanoparticles conjugate tested (Table S6).
The inﬂuence of the streptavidin-metal nanoparticle conjugates
concentration, as it was previously observed for CIA strategy, did
not have a signiﬁcant effect on the LoD (Table S7). Therefore, the
streptavidin-metal nanoparticles conjugate concentration was
again kept at 0.08 mgmL1 as compromise between analytical
performance and cost. Under these conditions, as it was previously
noticed for the CIA procedure, LoD for AFM1 determination was
independent on the streptavidin-metal nanoparticles conjugate
employed, both chemical nature and size (Fig. 5). Nevertheless,
steric effects were less signiﬁcant in the newapproach since LoD for
CBIA strategy (5 ng kg1) was improved 20-fold regarding CIA
strategy (Table 2). In general, no signiﬁcant differences were
observed on the dynamic range for both CIA and CBIA strategies.3.2. Comparison of the competitive immunoassays studied for AFM1
analysis
From data gathered in the previous section, the use of the pAb as
tracer species (as in the case of the ABIA procedure) seems to be
more advantageous than the use of the antigen-protein conjugate
as the tracer one (as in the case of CIA/CBIA strategies) for AFM1
analysis at ultratrace levels. Immunocomplex formation in the ABIA
strategy (unlike the other strategies) is not impeded by steric ef-
fects since, given the volume occupied by the BSA residues on the
solid phase, pAbs have enough space to form the immunocom-
plexes without interacting with their neighbours (Fig. 1). In this
case, the use of big diameter nanoparticles is indeed advantageous
to detect low amounts of pAb retained on the solid phase. In fact,
using streptavidin-80 nm Au nanoparticle conjugates, the LoD for
ABIA strategy was 1000-fold and 50-fold lower regarding CIA and
CBIA strategies, respectively. The LoD obtained with the ABIA
method (0.1 ng kg1) was low enough to quantify AFM1 according
to the different international policies. The European Community
legislation limits AFM1 levels in milk and infant formula at 50 and
25 ng kg1, respectively; [25,26] whereas Food and Drug Adminis-
tration from USA does allow AFM1 levels up to 500 ng kg1 [27]. As
regards CIA and CBIA strategies, steric effects control the immu-
nocomplex formation and, consequently, no direct advantages are
Fig. 5. Aﬂatoxin M1 calibration curve using different streptavidin-metal nanoparticle
conjugates for the CBIA procedure. (x) Ag-40 nm; ( ) Ag-80 nm; ( ) Au-40 nm; ( ) Au-
80 nm. Aﬂatoxin M1-BSA conjugate: 1 mgmL1; pAb concentration: 2.0 mgmL1; bio-
tinylated AFM1-BSA conjugate: 0.04 mgmL1 and streptavidin-metal nanoparticle
conjugates concentration: 0.08 mgmL1. Each bar represents the mean± t$s$n1/2 from
three determinations (P¼ 95%).
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ture and size. Nevertheless, LoD afforded by CBIA (namely,
5 ng kg1) was still low enough to control AFM1 levels according to
international policies. Regarding the CIA method (with a LoD of
100 ng kg1), it can only be used to control the AFM1 levels ac-
cording to USA guidelines but no according to EU ones. On the other
hand, an additional beneﬁt derived from ABIA strategy was the
reduction of the amount of pAb required in the immunoassay
procedure by two orders of magnitude regarding CIA and CBIA
strategies, thus decreasing immunoassay costs. Nevertheless, this
cost reduction is counterbalanced by the need of a secondary Ab.
The main beneﬁt of using CIA and CBIA methods is the higher
sample throughput since the whole immunoassay procedure takes
a shorter time. Finally, no signiﬁcant differences were noticed on
the immunoassay dynamic range.3.3. Method validation for AFM1 analysis in milk
Both ABIA and CBIA methods were validated for AFM1 analysis
in milk samples according to European Conformity guidelines for
analytical methods of food contaminants and mycotoxins [25,26].
Capture inhibition assay strategy was discarded due to its limited
capability to control AFM1 levels according to EU policy. Strepta-
vidin-80 nm Au nanoparticle conjugates were used for AFM1Table 3
Recovery analysis of AFM1 by ABIA and CBIA methods. Sample pretreatment: ABIA: 4-fo
Immuoassay Sample AFM1 c
Certiﬁe
ABIA ERM®-BD283 11.1± 1
Commercial whole milk 80
Commercial whole milk 30
Commercial fresh milk 80
Commercial fresh milk 30
CBIA ERM®-BD283 11.1± 1
Commercial whole milk 80
Commercial whole milk 32
Commercial fresh milk 80
Commercial fresh milk 32
a Mean± t$s$n1/2, n¼ 5, P¼ 95%.determination bymeans of ABIAmethod due to its higher detection
capabilities. As regards CBIA strategy, though the metal nano-
particle characteristics were not critical, 80 nm Au nanoparticles
were employed for the sake of comparison. To evaluate the accu-
racy and precision of the methods, they were applied to the
determination of AFM1 in the ERM-BD283 milk powder reference
material and recovery studies were carried out by spiking milk
samples with AFM1 standard at concentration levels over
(80 ng kg1) and below (30 ng kg1) the limits established by the
EU policy.
Initially, irrespective of the immunoassay procedure employed,
all milk samples were analyzed after an extraction pretreatment
with acetonitrile to mitigate the effects of matrix components (i.e.,
proteins, fats, etc.). This procedure was selected due to its simplicity
and the good results afforded in our previous work using strepta-
vidin-40 nm Au nanoparticle conjugates in the ABIA strategy [13].
However, AFM1 recoveries were systematically higher than 100%
for both ABIA and CBIA procedures using streptavidin-80 nm Au
nanoparticle conjugates (Table S8). From these results, it can be
derived that both types of immunoassays suffer from strong matrix
effects caused by the milk components that are still present in the
acetonitrile extract phase. In the case of ABIA strategy, these results
could be attributed to the lower pAb concentration employed since
it makes the immunoassay more sensitive to lower AFM1 concen-
trations but also tomatrix components. Taking into account the LoD
afforded by the ABIA method, milk samples could be diluted to
mitigate matrix effects without compromising analyte quantiﬁca-
tion [12]. To this end, before the extraction pretreatment, milk
samples were diluted with the appropriate volume of ultrapure
water. It was observed that matrix effects disappeared after a 4-fold
milk dilution (Table S8). Table 3 shows the recovery values obtained
for AFM1 determination in the certiﬁed reference material and in
the spiked milk samples by means of ABIA strategy after 4-fold
dilution. As can be observed, good recoveries in the ranged of
93e102% were obtained. These values were within the limits
established by the EU for analyte concentrations below 1 mg kg1
(40%/þ20%). Taking into account the sample preparation pro-
cedure applied, LoD for AFM1 determination by means of ABIA
strategy was experimentally determined as 0.4 ng kg1. The
repeatability or intra-day precision was evaluated by analyzing ﬁve
replicates of each sample in the same day. The reproducibility
(inter-assay precision) was determined by analyzing ﬁve replicated
samples, which were spiked with the same amount of AFM1, in ﬁve
consecutive days. The intra- and inter-day precisions were
expressed as the percentage relative standard deviation (RSD%).
The RSDs were ranged from 2 to 10% and 5e15% for intra-day and
inter-day variations respectively, which indicates good precision of
the ABIA method.
As regards the CBIA strategy, the poor recoveries obtained forld dilution þ acetonitrile extraction; CBIA: immunocolumns.
oncentration (ng kg1) Recovery (%)a
d/expected Experimentala
.8 11± 1 99± 7
81± 9 101± 8
29± 3 96± 8
81± 4 101± 7
31.5± 1.3 105± 4
.8 11.3± 1.2 102± 11
77± 8 95± 11
33± 4 102± 12
75± 10 93± 13
31± 2 97± 8
Table 4
Comparison of different analytical methods proposed in the literature for AFM1 determination in milk samples.
Method Recovery
(%)
Precision
(%)
LOD (ng
kg1)
Dynamic range (ng
kg1)
Reference
Immunoassays ABIA- ICPMS 98e107 <9 0.4 1.2e1200 This work
CBIA-ICPMS 93e102 <10 0.1 0.3e50 This work
Direct competitive ELISA (UV-Vis detection) 90e110 <10 3 e [28]
Direct competitive ELISA (chemiluminiscente detection) 80e120 <10 1 2e7.5 [29]
Indirect competitive ELISA (UV-Vis detection) 80e102 5e17 40 40e500 [30]
Liquid
chromatography
Highly-sensitive time-resolved ﬂuorescent immunochromatographic
assay
80e110 5e12 0.3 0.1e200 [31]
UHPLC-MS/MS 79 <15 0.18 50e500000 [32]
Solid phase extraction-UPLC-MS/MS 89e120 2e9 0.3 1e300 [33]
Liquid-liquid extraction HPLC-Fluorescence detection 73e99 2e7 50 e [34]
Magnetic solid phase extraction-HPLC- Fluorescence detection 91e102 5 5 15e10000 [35]
Sensors Electrochemical immunosensor e e 12 15e1000 [36]
Flow injection immunoassay 80e120 8 11 20e500 [37]
E. Perez et al. / Analytica Chimica Acta 1049 (2019) 10e1918milk analysis after the extraction pretreatment could be attributed
to the inﬂuence of matrix components on the biotinylated AFM1-
BSA-pAb immunocomplex formation and its retention on the mi-
crotiter plate. Unlike ABIA method, dilution could not be employed
in this case since LoD would compromise AFM1 determination ac-
cording to EU policy. Consequently, dilution was discarded, and an
extraction procedure based on the use of immunocolumns was
selected. This approach made feasible AFM1 analysis but at the
expense of a precision decrease (Table 3). The RSD for intra-assay
and inter-assay determination of AFM1 was over 10%. Due to the
extraction-preconcentration pretreatment, LoD for CBIA strategy
was approximately improved 50-fold (i.e. 0.1 ng kg1) and, conse-
quently, detection capabilities for CBIA strategy were similar to
those shown by ABIA method.
Finally, both methods were applied to the analysis of commer-
cial products (i.e. raw, pasteurized and ultra-high temperature
pasteurized milk) obtained from retail markets and supermarkets.
However, as expected, none of them showed detectable levels of
AFM1.3.4. Comparison of different methodologies for AFM1 determination
Analytical ﬁgures of merit of ABIA and CBIA procedures were
compared with those previously reported in the literature for AFM1
determination in milk (Table 4). Comparing to other competitive
immunoassays and sensors, the LoD and the dynamic range are
clearly improved by the immunoassays with ICP-MS detection. For
instance, LoD improvement afforded by ABIA and CBIA range from 3
to 100-fold regarding ELISA procedures. Nevertheless, sample
throughput is slightly reduced due to the sequential nature of the
mass spectrometer. Antibody binding inhibition assay affords
similar LoD than chromatographic methods but avoiding complex
sample pretreatments based on solid phase extraction (such as
immunocolumns) to preconcentrate and purify the AFM1. In this
regard, CBIA strategy is clearly less attractive since immuno-
columns are mandatory for AFM1 analysis. The main beneﬁt of
chromatographic methods is the feasibility to analyze several af-
latoxins simultaneously.4. Conclusions
This work demonstrates the critical role that plays the tracer
species (i.e. antibody or antigen-protein conjugate) used in the
competitive immunoassay for the aﬂatoxin M1 determination by
ICP-MS. Using the antibody as tracer species (as in the ABIA strat-
egy), the nanoparticle-label exerts a great inﬂuence on the immu-
noassay experimental conditions and, consequently, on theanalytical ﬁgures of merit. This type of immunoassay affords better
analytical ﬁgures of merit and lower matrix effects than those
based on the use of antigen-protein conjugate as tracer species (CIA
and CBIA strategies). The immunocomplex formation in the latter
approach is severely hampered by steric effects caused by the
protein moiety in the antigen-protein conjugate. According to these
results, competitive immunoassays based on the use of antibodies
as tracer species seem to be more suitable for hapten analysis by
means of ICP-MS detection since this strategy exploits better the
detection capabilities afforded by this technique. On this regard, it
is important to highlight that the use of ICP-MS detection is espe-
cially advantageous for ultra-trace determination of AFM1 in milk
samples regarding other detection approaches.
Acknowledgments
The authors would like to thank the Generalitat Valenciana
(Project GV/2014/138) and the Vice-Presidency for Research and
Knowledge Transfer of the University of Alicante e Spain for the
ﬁnancial support of this work (Project GRE12-19). E. Perez also
thanks the University of Alicante e Spain for the fellowship
(UAFPU2011).
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.aca.2018.11.024.
References
[1] J. Bettmer, M. Montes-Bayon, J. Ruiz Encinar, M.L. Fernandez, M. Fernandez de
la Campa, A. Sanz-Medel, The emerging role of ICP-MS in proteomic analysis,
J. Proteoms. 72 (2009) 989e1005.
[2] G. Grindlay, J. Mora, M.T.C. de Loos-Vollebregt, F. Vanhaecke, A systematic
study on the inﬂuence of carbon on the behavior of hard-to-ionize elements in
inductively coupled plasma-mass spectrometry, Spectrochim. Acta, Part B 86
(2013) 42e49.
[3] S. Bomke, M. Sperling, U. Karst, Organometallic derivatizing agents in bio-
analysis, Anal. Bioanal. Chem. 397 (2010) 3483e3494.
[4] D. Kretschy, G. Koellensperger, S. Hann, Elemental labelling combined with
liquid chromatography inductively coupled plasma mass spectrometry for
quantiﬁcation of biomolecules: a review, Anal. Chim. Acta 750 (2012) 98e110.
[5] C. Giesen, L. Waentig, U. Panne, N. Jakubowski, History of inductively coupled
plasma mass spectrometry-based immunoassays, Spectrochim. Acta, Part B 76
(2012) 27e39.
[6] R. Liu, P. Wu, L. Yang, X. Hou, Y. Lv, Inductively coupled plasma mass spec-
trometry based immunoassay: a review, Mass Spectrom. 33 (2014) 373e393.
[7] T. Konz, E. A~non Alvarez, M. Montes-Bayon, A. Sanz-Medel, Antibody labeling
and elemental mass spectrometry (inductively coupled plasma-mass spec-
trometry) using isotope dilution for highly sensitive Ferritin determination
and iron-Ferritin ratio measurements, Anal. Chem. 85 (2013) 8334e8340.
[8] A.P. Deng, H.T. Liu, S.J. Jiang, H.J. Huang, C.W. Ong, Reaction cell inductively
coupled plasma mass spectrometry-based immunoassay using ferrocene
E. Perez et al. / Analytica Chimica Acta 1049 (2019) 10e19 19tethered hydroxysuccinimide ester as label for the determination of 2,4-
dichlorophenoxyacetic acid, Anal. Chim. Acta 472 (2002) 55e61.
[9] G. Schwarz, L. Mueller, S. Beck, M.W. Linscheid, DOTA based metal labels for
protein quantiﬁcation: a review, J. Anal. Atom. Spectrom. 29 (2014) 221e233.
[10] C. Zhang, F. Wu, X. Zhang, ICP-MS-based competitive immunoassay for the
determination of total thyroxin in human serum, J. Anal. Atom. Spectrom. 17
(2002) 1304e1307.
[11] E. Perez, K. Bierla, G. Grindlay, J. Szpunar, J. Mora, R. Lobinski, Lanthanide
polymer labels for multiplexed determination of biomarkers in human serum
samples by means of size exclusion chromatography-inductively coupled
plasma mass spectrometry, Anal. Chim. Acta 1018 (2018) 7e15.
[12] C. Giensen, N. Jakubowski, U. Panne, M.G. Weller, Comparison of ICPMS and
photometric detection of an immunoassay for the determination of ochra-
toxin A in wine, J. Anal. Atom. Spectrom. 25 (2010) 1567e1572.
[13] E. Perez, P. Martínez-Peinado, F. Marco, L. Gras, J.M. Sempere, J. Mora,
G. Grindlay, Determination of aﬂatoxin M1 in milk samples by means of an
inductively coupled plasma mass spectrometry-based immunoassay, Food
Chem. 230 (2017) 721e727.
[14] P. Jarujamrus R. Chawengkirttikul, J. Shiowatana, A. Siripinyanond, Towards
chloramphenicol detection by inductively coupled plasma mass spectrometry
(ICP-MS) linked immunoassay using gold nanoparticles (AuNPs) as element
tags, J. Anal. Atom. Spectrom. 27 (2012) 884e890.
[15] A.R. Montoro Bustos, L. Trapiella-Alfonso, J.R. Encinar, J.M. Costa-Fernandez,
R. Pereiro, A. Sanz-Medel, Elemental and molecular detection for Quantum
Dots-based immunoassays: a critical appraisal, Biosens. Bioelectron. 33 (2012)
165e171.
[16] D. Wild, The Immunoassay Handbook: Theory and Applications of Ligand
Binding, ELISA and Related Techniques, fourth ed., Elsevier, Amsterdam, 2013.
[17] L. Trapiella-Alfonso, J.M. Costa-Fernandez, R. Pereiro, A. Sanz-Medel, Devel-
opment of a quantum dot-based ﬂuorescent immunoassay for progesterone
determination in bovine milk, Biosens. Bioelectron. 26 (2011) 4753e4759.
[18] W. Chen, P. Wee, I.D. Brindle, Elimination of the memory effects of gold,
mercury and silver in inductively coupled plasma atomic emission spectros-
copy, J. Anal. Atom. Spectrom. 15 (2000) 409e413.
[19] F. Vanhaecke, H. Vanhoe, R. Dams, C. Vandecasteele, The use of internal
standards in ICP-MS, Talanta 39 (1992) 737e742.
[20] L.C. Huang, N. Zheng, B.Q. Zheng, F. Wen, J.B. Cheng, R.W. Han, X.M. Xu, S.L. Li,
J.Q. Wang, Simultaneous determination of aﬂatoxin M1, ochratoxin A, zear-
alenone and a-zearalenol in milk by UHPLCeMS/MS, Food Chem. 146 (2014)
242e249.
[21] J.R. Crowter, The ELISA Guidebook, second ed., Humana press, New Jersey,
2001.
[22] S.J. Gee, T. Miyamoto, M.H. Goodrow, D. Buster, B.D. Hammock, Development
of an enzyme-linked immunosorbent assay for the analysis of the thio-
carbamate herbicide molinate, J. Agric. Food Chem. 36 (1988) 863e870.
[23] W. Jiang, Z. Wang, G. Nolke, J. Zhang, L. Niu, J. Shen, Simultaneous determi-
nation of aﬂatoxin B1 and aﬂatoxin M1 in food matrices by enzyme-linked
immunosorbent assay, Food Anal. Meth. 6 (2013) 767e774.[24] Guidance for Industry, Bioanalytical Method Validation, US Department of
Health and Human Services, Food and Drug Administration Centre for Drug
Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May
2001.
[25] EC, Commission Regulation (EC) No. 1881/2006 of 19 December 2006 setting
maximum levels for certain contaminants in foodstuffs, Ofﬁc. J. Eur. Union L
364 (2006) 5e24.
[26] EC, Commission regulation, regards aﬂatoxins and ochratoxin a in foods for
infants and young children, Ofﬁc. J. Eur. Union L 106 (2004) 5e24.
[27] FDA, Sec, 527.400 Whole Milk, Low Fat Milk, Skim Milk e Aﬂatoxin M1
(CPG7106.10), FDA/ORA Compliancy Guides, 2005.
[28] D. Guan, P. Li, W. Zhang, D. Zhang, J. Jiang, An ultra-sensitive monoclonal
antibody-based competitive enzyme immunoassay for aﬂatoxin M1 in milk
and infant milk products, Food Chem. 125 (2011) 1359e1364.
[29] M.M. Vdovenko, C.C. Lu, F.Y. Yu, I.Y. Sakharov, Development of ultrasensitive
direct chemiluminescent enzyme immunoassay for determination of aﬂatoxin
M1 in milk, Food Chem. 158 (2014) 310e314.
[30] S.C. Pei, Y.Y. Zhang, S.A. Eremin, W.J. Lee, Detection of aﬂatoxin M1 in milk
products from China by ELISA using monoclonal antibodies, Food Contr. 20
(2009) 1080e1085.
[31] X. Tang, Z. Zhang, P. Li, Q. Zhang, J. Jiang, D. Wang, J. Lei, Sample-pretreat-
ment-free based high sensitive determination of aﬂatoxin M1 in raw milk
using a time-resolved ﬂuorescent competitive immunochromatographic
assay, RSC Adv. 5 (2015) 558e564.
[32] W.L. Chen, T.F. Hsu, C.Y. Chen, Measurement of aﬂatoxin M1 in milk by utra-
high-performance liquid chromatography/tandem mass spectrometry,
J. AOAC Int. 94 (2011) 872e877.
[33] X. Wang, P. Li, Rapid screening of mycotoxins in liquid milk and milk powder
by automated size-exclusion SPE-UPLCeMS/MS and quantiﬁcation of matrix
effects over the whole chromatographic run, Food Chem. 173 (2015)
897e904.
[34] P. Diniz Andrade, J. Laine Gomez da Silva, E. Dutra Caldas, Simultaneous
analysis of aﬂatoxins B1, B2, G1, G2, M1 and ochratoxin A in breast milk by
high-performance liquid chromatography/ﬂuorescence after liquid-liquid
extraction with low temperature puriﬁcation (LLE-LTP), J. Chromatogr. A
1304 (2013) 61e68.
[35] M. Hashemi, Z. Taherimaslak, Determination of aﬂatoxin M1 in liquid milk
using high performance liquid chromatography with ﬂuorescence detection
after magnetic solid phase extraction, RSC Adv. 4 (2014) 33497e33506.
[36] A. Vig, X. Mu~noz-Berbel, A. Radoi, M. Cortina-Puig, J.L. Marty, Characterization
of the gold-catalyzed deposition of silver on graphite screen-printed elec-
trodes and their application to the development of impedimetric immuno-
sensors, Talanta 80 (2009) 942e946.
[37] M. Badea, L. Micheli, M.C. Messia, T. Candigliota, E. Marconi, T. Mottram,
M. Velasco-Garcia, D. Moscone, G. Palleschi, Aﬂatoxin M1 determination in
raw milk using a ﬂow-injection immunoassay system, Anal. Chim. Acta 520
(2004) 141e148.
